Fabrice André
Breast cancer geneticist who led SOLAR-1 and the SAFIR precision-medicine trials; ESMO President 2025-2026.
Fabrice André directs research at Gustave Roussy and leads the breast cancer genomics programme. He was principal investigator of SOLAR-1 (alpelisib), led the SAFIR01/02 genomics-guided trials, and served as ESMO President for 2025-2026.
Pages like this
not linked directly; found by shared links- PairingPI3K/AKT-pathway inhibitor + endocrine therapy (± CDK4/6)
Shares Alpelisib, PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
- InstitutionINCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia
Shares European Society for Medical Oncology (ESMO), Comprehensive genomic profiling, HR-positive / HER2-negative breast cancer.
- PersonRamon E. Parsons
Shares PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
- TrialINAVO120
Shares PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
- TrialCAPItello-291
Shares PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
- ProductGedatolisib
Shares PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
- InstitutionVanderbilt-Ingram Cancer Center
Shares PIK3CA / PI3K-alpha, Comprehensive genomic profiling.
- IdeaGet biomarker-directed aspirin after colorectal surgery into labels and guidelines
Shares PIK3CA / PI3K-alpha, European Society for Medical Oncology (ESMO).